ArticleNature2025
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- NNMT-associated metabolic-thromboinflammatory-immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework".BMC cancer · 2026Article
- Lactate as a Master Regulator of Immune Suppression: From Metabolic Waste to Epigenetic Checkpoint in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Review
- Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.Biomarker research · 2026Review
- CAF-derived exosomes inhibit ferroptosis via GALNT14-mediated O-GalNAcylation of SLC7A11 in colorectal cancer.Oncogene · 2026Article
- Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment.Oncogene · 2026Article
- Spatiotemporally Ultrasound-Controlled Nanoparticles Reprogramming Immunostimulatory Antigen-Presenting Cancer-Associated Fibroblasts to Enhance Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity.Cancer metastasis reviews · 2026Review
- Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer.Research square · 2026Article
- Fibroblast-specific ablation of MHC-I antigen presentation via the IGF2 axis cripples CD8Science advances · 2026Article
- Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.Cancer cell · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Engineered zwitterion-nanodelivery for precision targeting of brain metastases.Nature communications · 2026Article
- Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.Journal of hematology & oncology · 2026Article
- NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation.bioRxiv : the preprint server for biology · 2026Article
- Article
- Multi-Omics profiling identify NNMT in tumor endothelium as a key regulator of CD8⁺ T cell exhaustion via the TGF signaling pathway.Translational oncology · 2026Article
- [Current oncology (Toronto, Ont.) · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- NNMT and the methylation sink: integrating metabolism, epigenetics and immunity in cancer.BMC medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Janna HeideDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-3528-1602
Agnes J Bilecz *Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Samarjit Patnaik *National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-4265-7620
Maria Francesca Allega *Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-0952-8496
Leonhard DonleDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Kaiting YangDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-9328-5655
Ethan TeichDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.ORCID 0009-0000-4890-4445
Yan LiCenter for Research Informatics, University of Chicago, Chicago, IL, USA.
Qiaoshan LinCenter for Research Informatics, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-7851-6048
Ke KongNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Li LiuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Tae Gyun YangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Ken Chih-Chien ChengNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Jonathan H ShrimpNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Quinlin M HansonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Min ShenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Hongmao SunNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Hardik ShahMetabolomics Platform, Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-8408-5686
Lisa SchweizerDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-1165-7804
Katarzyna ZawieraczDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Andrea OllandSchrödinger Framingham, Framingham, MA, USA.
Andre WhiteSchrödinger Framingham, Framingham, MA, USA.ORCID 0000-0002-4393-1062
Robert K SutoSchrödinger Framingham, Framingham, MA, USA.
Razzaq AlhunayanDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.ORCID 0009-0005-5629-0881
Medine TaşdemirDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Noa LongmanDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Hua LiangDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-5512-8595
Matthias MannDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0003-1292-4799
Gordon M StottLeidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-9148-6100
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-5073-442X
Simon SchwörerDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-5643-8939
András PiffkóDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-5300-6594
Ernst LengyelDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA. elengyel@uchicago.edu.ORCID 0000-0001-8624-1507
Funding
Metabolic reprogramming of the tumor microenvironment and therapy resistanceR35CA264619 · NCI · UNIVERSITY OF CHICAGO · PI Ernst Lengyel · 2021 to 2026
$5.2MElucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapyR01CA262508 · NCI · UNIVERSITY OF CHICAGO · PI WEICHSELBAUM, RALPH R · 2021 to 2025
$2.0MNicotinamide N-Methyltransferase (NNMT) as a master regulator of cancer stromaR01CA211916 · NCI · UNIVERSITY OF CHICAGO · PI LENGYEL, ERNST · 2017 to 2021
$1.9MInvestigating the metabolic regulation of tumor desmoplasiaR00CA259224 · NCI · UNIVERSITY OF CHICAGO · PI SCHWÖRER, SIMON · 2023 to 2025
$747kNCI NIH HHS R00 CA259224NCI NIH HHS R01 CA211916NCI NIH HHS R01 CA262508NCI NIH HHS R35 CA264619
Abstract
Cancer-associated fibroblasts (CAFs) have a pivotal cancer-supportive role, yet CAF-targeted therapies are lacking
Indexed as
Cancer-Associated FibroblastsEnzyme InhibitorsNicotinamide N-MethyltransferaseOvarian NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorColonic NeoplasmsFemaleHistonesHumansImmune Checkpoint InhibitorsLymphocyte ActivationMaleMethylationMiceEnzyme InhibitorsHistonesImmune Checkpoint InhibitorsNicotinamide N-Methyltransferase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.